Skip to main content
. 2016 Oct 17;3:826–831. doi: 10.1016/j.toxrep.2016.10.004

Table 2.

Distribution of NAT2 genotypes and predicted acetylator phenotype (n = 96).

Genotype Number of subjects Observed frequency (%) Predicted phenotype
NAT2*5/*5 5 5.2 Slow
NAT2*5/*6 16 16.7 Slow
NAT2*5/*7 4 4.2 Slow
NAT2*5/*14 10 10.4 Slow
NAT2*6/*6 7 7.3 Slow
NAT2*6/*7 1 1 Slow
NAT2*6/*14 4 4.2 Slow



Total Lent 47 49
NAT2*4/*4 1 1 Rapid
NAT2*4/*5 1 1 Rapid
NAT2*4/*6 7 7.3 Rapid
NAT2*4/*12 3 3.1 Rapid
NAT2*4/*13 6 6.3 Rapid
NAT2*4/*14 2 2.1 Rapid
NAT2*5/*12 9 9.4 Rapid
NAT2*6/*12 4 4.2 Rapid
NAT2*6/*13 4 4.2 Rapid
NAT2*7/*13 1 1 Rapid
NAT2*12/*12 1 1 Rapid
NAT2*12/*13 4 4.2 Rapid
NAT2*13/*13 1 1 Rapid
NAT2*13/*14 3 3.1 Rapid



Total Rapide 47 49
NAT2*6/*new (838) 1 1 Unknown
NAT2*5/*12H 1 1 Unknown
Total Unknowna 2 2
Total 96 100
a

Two out of the 96 tested subjects had an unknown acetylator phenotype as they were composite heterozygotes for a slow-acetylator allele and an allele with unknown functional effect.